Promising drug for rare blinding eye disease tested in small trial
NCT ID NCT00584935
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This early-phase trial tested the drug rituximab in 3 people with ocular cicatricial pemphigoid, a rare autoimmune disease that scars the eye and can lead to blindness. The goal was to see if rituximab could stop further scarring when standard treatments had failed. The study measured scarring and side effects over several weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR CICATRICIAL PEMPHIGOID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.